Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial

@article{Alvarezlerma2001EfficacyAT,
  title={Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial},
  author={F. Alvarez-lerma and Josu Insausti-Orde{\~n}ana and Ricard Jord{\`a}-Marcos and Enrique Marav{\'i}-Poma and A Torres-Mart{\'i} and Juan Manuel Nava and Antonio Mart{\'i}nez-Pell{\'u}s and Mercedes Palomar and F. Barcenilla and the Spanish Collaborative Group for},
  journal={Intensive Care Medicine},
  year={2001},
  volume={27},
  pages={493-502}
}
Abstract. Objective: To compare clinical and bacteriological efficacy as well as tolerability of two regimens of broad-spectrum antibiotics (ceftazidime versus piperacillin/tazobactam) combined with amikacin in the treatment of nosocomial pneumonia in intensive care patients. Design: Open label, prospective, multicenter, and randomized phase III clinical trial. Setting: Medical or surgical intensive care units (ICUs) of nine acute-care teaching hospitals in Spain. Patients and participants: One… 

Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study*

Doripenem was clinically and microbiologically effective in patents with NP, including those with early-onset ventilator-associated pneumonia, and was therapeutically noninferior to piperacillin/tazobactam.

Piperacillin/Tazobactam vs Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia—a Double Blind Prospective Multicentre Study

Although numbers were inadequate for full statistical evaluation, P/T and I/C were similarly effective in the treatment of severe nosocomially acquired pneumonia.

Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study

This study mainly highlights the current practice of a specific algorithm of de-escalation solely based on the available microbiological data, and highlights the barriers to using it more widely.

Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime.

The authors were unable to detect a statistically significant difference in ARF between groups; however, the power requirement was not met, and further study with a larger patient population seems warranted.

Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.

Intravenous colistin appears to be a safe and effective alternative to imipenem for the management of VAP due to carbapenem-resistant strains of A. baumannii.

Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia*

A target piperacillin serum concentration of at least 35–40 mg/L is probably required to provide alveolar concentrations exceeding the susceptibility breakpoint for Gram-negative bacteria during ventilator-associated pneumonia, suggesting that therapeutic drug monitoring should be performed in order to adjust the daily dose.

Research Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational

Higher Acute Physiology, Age, and Chronic Health Evaluation II scores were associated with greater mortality, whereas adequate empiric antibiotic therapy protected against fatal outcomes, and the costs associated with de-escalation were mainly dependent on the duration of hospitalization.

Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia

The results show that during the treatment of severe nosocomial pneumonia, a regimen of P/T 4 g/0.5 g every 8 h might provide insufficient concentrations into lung tissue to exceed the MIC of many causative pathogens.

The Efficacy of Piperacillin/Tazobactam in Experimental Pseudomonas aeruginosa Endophthalmitis: A Histopathological and Microbiological Evaluation

Intravitreal piperacillin/tazobactam combination may be a new therapy for P. aeruginosa endophthalmitis in rabbits, and the mean histopathological score of group 2 was significantly higher than group 2 (p = 0.009).

Ceftazidime for respiratory infections

  • S. ChoiY. Koh
  • Medicine, Biology
    Expert opinion on pharmacotherapy
  • 2012
To maintain or improve the clinical use of ceftazidime in patients with severe HAP, it will be essential to gain a thorough understanding of local resistance patterns, and judiciously use antimicrobial agents through individualization of antimicrobial therapy for HAP.
...